KENT AND MEDWAY HEALTH ECONOMY NATIONAL TARIFF EXCLUDED DRUGS Summary of Current Arrangements 2017/18 Contents NATIONAL TARIFF EXCLUDED DRUGS: SUMMARY OF CURRENT ARRANGEMENTS .................................. 10 MANAGEMENT OF NATIONAL TARIFF EXCLUDED DRUGS ...................................................................... 11 Payment Arrangements ................................................................................................................................... 12 Responsibilities ................................................................................................................................................ 12 Amendment Sheet ........................................................................................................................................... 13 3, 4 DIAMINOPYRIDINE .................................................................................................................................... 15 ABACAVIR ......................................................................................................................................................... 16 ABACAVIR with DOLUTEGRAVIR and LAMIVUDINE ......................................................................................... 17 ABACAVIR with LAMIVUDINE ........................................................................................................................... 18 ABALOPARATIDE .............................................................................................................................................. 19 ABATACEPT ...................................................................................................................................................... 20 ABATACEPT (CCG) ............................................................................................................................................ 21 ABIRATERONE .................................................................................................................................................. 22 ADALIMUMAB .................................................................................................................................................. 23 ADALIMUMAB (CCG) ........................................................................................................................................ 24 ADEFOVIR ......................................................................................................................................................... 25 AFAMELANOTIDE ............................................................................................................................................. 26 AFATINIB .......................................................................................................................................................... 27 AFLIBERCEPT .................................................................................................................................................... 28 AFLIBERCEPT (CCG) .......................................................................................................................................... 29 AGALSIDASE ALFA ............................................................................................................................................ 30 AGALSIDASE BETA ............................................................................................................................................ 31 AGANIRSEN ...................................................................................................................................................... 32 ALBUTREPENONACOG ALFA ............................................................................................................................ 33 ALDESLEUKIN ................................................................................................................................................... 34 ALEMTUZUMAB ............................................................................................................................................... 35 ALGLUCOSIDASE ALFA ...................................................................................................................................... 36 ALIPOGENE TIPARVOVEC ................................................................................................................................. 37 ALIROCUMAB ................................................................................................................................................... 38 ALITRETINOIN ................................................................................................................................................... 39 ALPHA-1 ANTITRYPSIN ..................................................................................................................................... 40 ALPHA MANNOSIDASE RECOMBINANT HUMAN ............................................................................................. 41 AMBRISENTAN ................................................................................................................................................. 42 AMIFAMPRIDINE PHOSPHATE ......................................................................................................................... 43 AMIKACIN INHALATION ................................................................................................................................... 44 AMIKACIN LIPOSOMAL .................................................................................................................................... 45 AMPHOTERICIN LIPOSOMAL ............................................................................................................................ 46 ANAKINRA ........................................................................................................................................................ 47 ANAKINRA (CCG) .............................................................................................................................................. 48 ANIDULAFUNGIN.............................................................................................................................................. 49 ANTIHAEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX .............................................................. 50 ANTILYMPHOCYTE GLOBULIN .......................................................................................................................... 51 ANTITHROMBIN III ........................................................................................................................................... 52 ANTITHYMOCYTE IMMUNOGLOBULIN ............................................................................................................ 53 APREMILAST ..................................................................................................................................................... 54 APREMILAST (CCG) ........................................................................................................................................... 55 ARAGAM® ........................................................................................................................................................ 56 1 ASFOTASE ALPHA ............................................................................................................................................. 57 ASUNAPREVIR with DACLATASVIR ................................................................................................................... 58 ATACICEPT ........................................................................................................................................................ 59 ATALUREN ........................................................................................................................................................ 60 ATAZANAVIR .................................................................................................................................................... 61 ATAZANAVIR and COBICISTAT ......................................................................................................................... 62 AVATROMBOPAG ............................................................................................................................................. 63 AXITINIB ........................................................................................................................................................... 64 AZACITIDINE ..................................................................................................................................................... 65 AZATHIOPRINE ................................................................................................................................................. 66 AZTREONAM LYSINE ........................................................................................................................................ 67 BARICITINIB ...................................................................................................................................................... 68 BARICITINIB (CCG) ............................................................................................................................................ 69 BASILIXIMAB ...................................................................................................................................................